Name of License: Notice of Intent to Grant an Exclusive License; SteroTherapeutics LLC
Summary: Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to SteroTherapeutics LLC, 3805 Old Easton Road Doylestown, Pennsylvania, 18902, USA, an exclusive license to international patent filing applicaton no. PCT/US2020/028445 (publication no. WO/2020/214,773), associated with VA Invention Disclosure number 2019-155 titled, “Galanin inhibitors for liver fibrosis treatment.”
Tech Name:
Galanin inhibitors for liver fibrosis treatment
Dates: Comments must be received on or before October 22, 2021.
Address: Send comments to Dr. Jenish Patel, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: [email protected]
For Further Information Contact: Dr. Jenish Patel, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: [email protected]
Supplementary Information: The Federal Government’s patent rights in this invention are assigned to the U.S. Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as SteroTherapeutics has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.